DailyMed: Wegovy prescribing information
Source of approved indication scope for semaglutide under this brand context.
Evidence memo
Semaglutide
Also tracked as: Wegovy, Ozempic, Rybelsus
An approved GLP-1 receptor agonist with extensive clinical data in diabetes, obesity, and selected cardiovascular-risk contexts.
Post-market evidence Approved specific use
Evidence status
Clinically established in specific contexts. Evidence level: Post-market evidence.
Claim being evaluated
Which benefits are supported within approved indications, and where wellness or longevity narratives go beyond the evidence.
Why people care
Semaglutide is a reference point for the current obesity-drug era and for debates about cardiometabolic risk reduction.
Signal so far
Large clinical programs and post-market use support specific approved contexts. Evidence strength is highest when claims stay inside labeled or trial-tested populations.
Biggest unknown
How to interpret long-term population use, discontinuation, access, rare risks, and broader claims outside studied contexts.
Safety/regulatory boundary
Approved use does not equal broad wellness proof. Compounded or identity-uncertain products are a separate risk category from labeled products.
Watch next
Long-term outcomes, safety surveillance, comparative data, access constraints, and how clinicians manage benefit-risk in different patient groups.
Evidence interpretation
Established in specific contexts, but not a blank-check longevity or wellness intervention.